Laboratory Control of Oral Anticoagulants

E. A Loeliger; J. B Meuwisse-Braun; H Muis; F. J. J Buitendijk; J. J Veltkamp; H. C Hemker

doi:10.1055/s-0038-1654188

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1970; 17(03): 569-584
DOI: 10.1055/s-0038-1654188

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Laboratory Control of Oral Anticoagulants

Definition of Therapeutic Range in Terms of Different Thromboplastin Preparations

Authors

E. A Loeliger

¹Haematology Section of the Department of Medicine, Leiden University Hospita and the Leiden Thrombosis Service
J. B Meuwisse-Braun

¹Haematology Section of the Department of Medicine, Leiden University Hospita and the Leiden Thrombosis Service
H Muis

¹Haematology Section of the Department of Medicine, Leiden University Hospita and the Leiden Thrombosis Service
F. J. J Buitendijk

¹Haematology Section of the Department of Medicine, Leiden University Hospita and the Leiden Thrombosis Service
J. J Veltkamp

¹Haematology Section of the Department of Medicine, Leiden University Hospita and the Leiden Thrombosis Service
H. C Hemker

¹Haematology Section of the Department of Medicine, Leiden University Hospita and the Leiden Thrombosis Service

Abstract

Summary

The therapeutic range in oral anticoagulation, which is defined as the range of hypocoagulability resulting in optimal thrombosis prophylaxis and an acceptable bleeding tendency, is monitored by assay procedures of which the majority are modifications of Quick’s original prothrombin time test. With respect to individual patients on stabilized anticoagulation, the different modifications commonly used give the same information, the reliability depending more on the accuracy than on the sensitivity of the tests. The results do not appear to be comparable in terms of conventional reference curves or prolongation ratios of the coagulation times found, but on the basis of painstakingly defined normal and patient plasma, the mean of the factor II and factor X activity present in patients’ plasma proved to be a useful common denominator. In terms of this common denominator, the therapeutic range to be aimed at lies between (8 to) 10 and 20(to 25)percent.

Full Text

References

References
1 Quick A. J, Stanley-Brown M, Bancroft F. W. A study of the coagulation defect in hemophilia and in jaundice. Amer. J. med. Sci 190: 501-511 1935;
2 Owren B. A. The P & P method. Scand. J. clin. Lab. Invest 3: 201-204 1951;
3 Owren P. A. “Thrombotest”: A new method for controlling anticoagulant therapy. Lancet 71: 754-758 1959;
4 Hemker H. C, Veltkamp J. J, Loeliger E. A. Kinetic aspects of the interaction of blood clotting enzymes. III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thrombos. Diathes. haemorrh. (Stuttg.) 19: 347-363 1968;
5 Miale J. B, Lafond D. J. 1963 Prothrombin time test survey, College of American Pathologists, Standard Committee, Subcommittee on Coagulation. Amer. J. clin. Path 47: 40-59 1967;
6 Bowerman D, Notestine H. Quality control in coagulation studies. An evaluation of control systems for plasma prothrombin determinations. Amer. J. clin. Path 39: 535-537 1969;
7 van Horn P. Quality control of prothrombin determinations. Normal and abnormal prothrombin activity levels. Amer. J. med. Technol 34: 1-8 1968;
8 Biggs R, Denson K. W. E. Standardization of the one-stage prothrombin time for the control of anticoagulant therapy. Brit. Med. J 1: 84-88 1967;
9 Loeliger E. A, Taconis W. K, Veltkamp J. J, Hemker H. G. Standardization of results obtained with different thromboplastin preparations. Conf. Int. Comm. Haemostasis Thrombosis, Princeton (1968).
10 Koller F, Loeliger E. A, Duckert F. Experiments on a new clotting factor. (Factor VII). Acta haemat. (Basel) 6: 1-18 1951;
11 Owren P. A. A quantitative one-stage method for the assay of prothrombin. Scand. J. clin. Lab. Invest 1: 81-83 1949;
12 Hemker H. G, Hemker P. W, Loeliger E. A. Kinetic aspects of the interaction of blood clotting enzymes. I. Derivation of basic formulas. Thrombos. Diathes. haemorrh. (Stuttg.) 13: 155-175 1965;
13 Borchgrevink G. F, Pool J. G, Stormorken H. A new assay for factor V (proaccelerin-accelerin) using Russell’s viper venom. J. Lab. clin. Med 55: 625-632 1960;
14 Lechner K, Deutsch E, Reimitzer I. Eine einfache Methode zur Herstellung von menschlichem Faktor-VII-Mangelplasma. Thrombos. Diathes. haemorrh. (Stuttg.) 18: 252-258 1967;
15 Loeliger E. A. Schlechte Eigenschaft langwirkender Cumarine oder für deren Kontrolle ungeeignete Thrombokinase ? Schweiz, med. Wschr 88: 639-643 1958;
16 de Vries S. I, Abels J, Haanen C. A. M, Loeliger E. A. De Thrombo-test van Owren. Ned. T. Geneesk 105: 977-980 1961;
17 Poller L. Methods for the laboratory control of short-term anticoagulant therapy. Acta haemat. (Basel) 28: 168-179 1962;
18 Loeliger E. A, Hensen A, Kroes F, van Dijk L. M, Fekkes N, Hemker H. C. A double-blind trial on long-term anticoagulant treatment after myocardial infarction. Acta med. scand 182: 549-566 1967;
19 Meuwissen O. J. A. Th, Vervoorn A. G, Cohen O, Jordan F. L. J. Interim report on the Utrecht Study of long-term anticoagulant therapy in occlusive coronary artery disease. Acta med. scand 186: 361-365 1969;
20 Roos J, van Joost H. E. The cause of bleeding during anticoagulant treatment. Acta med. scand 178: 129-131 1965;
21 Rozenberg M. G, Kronenberg H, Firkin B. G. “Thrombotest” and Prothrombin time: A controlled clinical trial. Aust. Ann. Med 14: 3-12 1965;
22 Sevitt S, Innes D. Prothrombin-time and Thrombotest in injured patients on prophylactic anticoagulant therapy. Lancet I: 124-129 1964;
23 Kuijer P. J, Leeksma G. H. W. Profylaxe van veneuze thromboembolische complicaties met behulp van anticoagulantia. Ned. T. Geneesk 109: 1480-1484 1965;
24 Report of the Working Party on Anticoagulant Treatment in Coronary Thrombosis to the Medical Research Council: Assessment of short-term anticoagulant administration after cardiac infarction. Brit. med. J 1: 335-342 1969;
25 Rabiner S. F. The relationship of coagulation defects to haemorrhage in patients receiving oral anticoagulants. Amer. J. med. Sci 249: 68-75 1965;
26 Beaumont P. M. Jaarverslag van de Thrombosedienst van het Nederlandsche Roode Kruis (1963).
27 Loeliger E. A, Hemker H. G. Principles of the mode of action of coumarin congeners. Proc. 3rd Int. Pharmacol Meeting Sao Paolo. Pergamon Press, Oxford & New York 6: 13-24 1968;
28 van der Esch B, Loeliger E. A. De werking van coumarinepreparaten op de bloedstolling bij hoge initiële dosering. Verslag 3e Conf. Thrombosediensten Nederlandsche Roode Kruis, Zeist.p.26 (1960).
29 Loeliger E. A, B. v. d. Esch M, Mattern J, den Brabander A. S. A. Behaviour of factor II, VII, IX, and X during long-term treatment with coumarin. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 75-89 1963;
30 Loeliger E. A, Hensen A, Mattern M. J, Hemker H. G. Behaviour of factors II, VII, IX, and X in bleeding complications during long-term treatment with coumarin. Thrombos. Diathes. haemorrh. (Stuttg.) 10: 278-281 1964;
31 Hemker H. G, Veltkamp J. J, Hensen A, Loeliger E. A. Nature of prothrombin biosynthesis: preprothrombinaemia in vitamin K-deficiency. Nature (Lond.) 200: 589-591 1963;
32 Hemker H. G, Annemarie Muller E, Loeliger A. Two types of prothrombin in vitamin K deficiency. Thrombos. Diathes. haemorrh. (Stuttg.) 23: 652 1970;
33 Hart H. Ch, Loeliger E. A. Een onderzoek naar de overerving van prothrombinedeficientie. Ned. T. Geneesk 107: 1107-1108 1963;
34 Meer J. van der, Hemker H. G, Loeliger E. A. Pharmacological aspects of vitamin K₁ . A clinical and experimental study in man. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 29 (1968).
35 Schrogie J. J, Solomon H. M, Zieve P. D. Effect of oral contraceptives on vitamin Independent clotting activity. Clin, pharmacol. Ther 8: 670-675 1967;
36 Murphy E. A. Proc. Conf. Int. Comm. Haemostasis and Thrombosis. Washington 1967.
37 Loeliger E. A, Hemker H. G. Considerations on an international standard for the one-stage prothrombin time in the control of anticoagulant therapy. Conf. Int. Comm. Haemostasis Thrombosis. Washington 1967.